marked.bio

MEK inhibitor · small molecule

selumetinib

7 active trials across 6 of our biomarkers, targeting MEK1/2. Not approved for any biomarker on marked.bio yet.

Also known as AZD6244, ARRY-142886, Koselugo.

Counts only trials that select patients by one of the biomarkers on marked.bio, not every trial of this drug.

Biomarkers

BiomarkerActive trialsAll trialsFurthest active phase
KRAS G12C 3 10 Phase 3
KRAS G12D 3 10 Phase 3
EGFR exon 19 deletion / L858R 2 3 Phase 2
BRAF V600E 1 6 Phase 1/2
FGFR2 fusion or rearrangement 1 1 Phase 1
FGFR3 alteration (mutation or fusion) 1 1 Phase 1

Sponsors

Industry sponsors leading active biomarker-selected trials of selumetinib.

  1. AstraZeneca 3

Trials

7 of 20 trials shown

  1. Assess Efficacy & Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Positive NSCLC

    Active, not recruiting Phase 3 AstraZeneca Started 2013Primary completion 2016-06 NCT01933932

    selumetinibdocetaxelpegfilgrastim

    KRAS mutation positive tumour sample as determined by the designated testing laboratory

    KRAS G12CKRAS G12DLocally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IV

  2. Testing the Combination of Anti-Cancer Drugs, Selumetinib and DS-8201a (Trastuzumab Deruxtecan), for Advanced Pancreatic Ductal Adenocarcinoma

    Recruiting Phase 1/2 National Cancer Institute (NCI) Starts 2027Primary completion 2028-09 NCT07619521

    selumetinibtrastuzumab deruxtecan

    Patients must have unresectable or metastatic disease with KRAS mutation per Next Generation Sequencing (NGS) tumor testing and HER2 immunohistochemistry (IHC) po…

    KRAS G12CKRAS G12DAdvanced Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Ductal Adenocarcinoma, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8

  3. Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial

    Active, not recruiting Phase 2 National Cancer Institute (NCI) Started 2023Primary completion 2026-09 NCT05554328

    olaparibselumetinib

    …hway mutant ovarian, primary peritoneal, or fallopian tube ("ovarian") cancer (activating mutations in KRAS, NRAS, HRAS, BRAF, MEK1, MEK2, or inactivating mutations in NF1)

    KRAS G12CKRAS G12DRecurrent Endometrial Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma

  4. A Phase 2 Study of Osimertinib in Combination With Selumetinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer

    Active, not recruiting Phase 2 Dana-Farber Cancer Institute Started 2018Primary completion 2027-06 NCT03392246

    osimertinib FDA EUselumetinib

    …e histologically confirmed stage IV NSCLC (per AJCC 7th edition) with either the L858R or exon 19 deletion activating EGFR mutation as identified in a CLIA-approved laboratory.

    EGFR exon 19 deletion / L858RNon-small Cell Lung Cancer

  5. Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma

    Active, not recruiting Phase 1/2 National Cancer Institute (NCI) Started 2010Primary completion 2026-01 NCT01089101

    selumetinib

    these patients must have both the BRAFV600E mutation and BRAF KIAA1549 fusion assessments done and if only one test was previously co…

    BRAF V600ELow Grade Glioma, Recurrent Childhood Pilocytic Astrocytoma, Recurrent Neurofibromatosis Type 1, Recurrent Visual Pathway Glioma

  6. Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder Cancer

    Active, not recruiting Phase 1 AstraZeneca Started 2016Primary completion 2020-03 NCT02546661

    fexagratinibdurvalumabolaparibadavosertibVistusertibAZD9150selumetinib

    Confirmation of FGFR3 mutation or FGFR fusion

    FGFR3 alteration (mutation or fusion)FGFR2 fusion or rearrangementMuscle Invasive Bladder Cancer

  7. AZD9291 in Combination With Ascending Doses of Novel Therapeutics

    Active, not recruiting Phase 1 AstraZeneca Started 2014Primary completion 2020-03 NCT02143466

    osimertinib FDA EUsavolitinibselumetinibdurvalumab

    …our harbours an EGFR mutation known to be associated with EGFR TKI sensitivity (including exon 19 deletion and L858R).

    EGFR exon 19 deletion / L858RAdvanced Non Small Cell Lung Cancer